Richard P. Harrison
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Richard P. Harrison has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
Nicholas Medcalf
Centre for Biological Engineering, Holywell Park, Loughborough University, Loughborough, United Kingdom
2 shared publications- Nicholas Medcalf
Centre for Biological Engineering, Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough, UK
2 shared publications - Qasim Ali Rafiq
Department of Biochemical Engineering University College London London UK
2 shared publications Steven Ruck
Centre for Biological Engineering, Holywell Park, Loughborough University, Loughborough LE11 3TU, UK
2 shared publications- Bruce L. Levine
Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, USA
1 shared publication Ezequiel Zylberberg
Akron Biotechnology, Boca Raton, Florida, USA; MIT Industrial Performance Center, Cambridge, Massachusetts, USA
1 shared publication
Latest Publications
- Open Access
- 1 February 2019
- Published by Elsevier in Cytotherapy
- Vol. 21 (2) , 224-233
Chimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
- 1 February 2019
- Published by Elsevier in Cytotherapy
- Vol. 21 (2) , 224-233
Open AccessChimeric antigen receptor–T cell therapy manufacturing: modelling the effect of offshore production on aggregate cost of goods
- Open Access
- 1 June 2018
- Published by Elsevier in Cytotherapy
- Vol. 20 (6) , 873-890
Centralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar
- 1 June 2018
- Published by Elsevier in Cytotherapy
- Vol. 20 (6) , 873-890
Open AccessCentralised versus decentralised manufacturing and the delivery of healthcare products: A United Kingdom exemplar
- Open Access
- 6 March 2018
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 13 (2) , 159-173
Cell Therapy-Processing Economics: Small-Scale Microfactories as a Stepping Stone Toward Large-Scale Macrofactories
Aim: Manufacturing methods for cell-based therapies differ markedly from those established for noncellular pharmaceuticals and biologics. Attempts to ‘shoehorn’ these into existing frameworks have yielded poor outcomes. Some excellent clinical results have been realized, yet emergence of a ‘blockbuster’ cell-based therapy has so far proved elusive. Materials & methods: The pressure to provide these innovative therapies, even at a smaller scale, remains. In this process, economics research paper, we utilize cell expansion research data combined with operational cost modeling in a case study to demonstrate the alternative ways in which a novel mesenchymal stem cell-based therapy could be provided at small scale. Results & Conclusions: This research outlines the feasibility of cell microfactories but highlighted that there is a strong pressure to automate processes and split the quality control cost-burden over larger production batches. The study explores one potential paradigm of cell-based therapy provisi...
- 6 March 2018
- Published by Taylor & Francis in Regenerative Medicine
- Vol. 13 (2) , 159-173
Open AccessCell Therapy-Processing Economics: Small-Scale Microfactories as a Stepping Stone Toward Large-Scale Macrofactories
Aim: Manufacturing methods for cell-based therapies differ markedly from those established for noncellular pharmaceuticals and biologics. Attempts to ‘shoehorn’ these into existing frameworks have yielded poor outcomes. Some excellent clinical results have been realized, yet emergence of a ‘blockbuster’ cell-based therapy has so far proved elusive. Materials & methods: The pressure to provide these innovative therapies, even at a smaller scale, remains. In this process, economics research paper, we utilize cell expansion research data combined with operational cost modeling in a case study to demonstrate the alternative ways in which a novel mesenchymal stem cell-based therapy could be provided at small scale. Results & Conclusions: This research outlines the feasibility of cell microfactories but highlighted that there is a strong pressure to automate processes and split the quality control cost-burden over larger production batches. The study explores one potential paradigm of cell-based therapy provisi...
- Open Access
- 1 March 2018
- Published by Elsevier in Biotechnology Advances
- Vol. 36 (2) , 345-357
Decentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors
- 1 March 2018
- Published by Elsevier in Biotechnology Advances
- Vol. 36 (2) , 345-357
Open AccessDecentralised manufacturing of cell and gene therapy products: Learning from other healthcare sectors
- Open Access
- 1 October 2017
- Published by Elsevier in Cytotherapy
- Vol. 19 (10) , 1140-1151
Decentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities
- 1 October 2017
- Published by Elsevier in Cytotherapy
- Vol. 19 (10) , 1140-1151
Open AccessDecentralized manufacturing of cell and gene therapies: Overcoming challenges and identifying opportunities